Philip Schoenfeld, MD, MSEd, MSc (Epi) and Swati Patel, MD, MS discuss “Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial,” by Burn J, Sheth H, Elliot F, et al. Lancet 2020;395:1855-63.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MS discuss “Etrasimod as Induction and Maintenance Therapy for Ulcerative Colitis (ELEVATE): Two Randomised, Double-Blind, Placebo-Controlled, Phase 3 Studies,” by Sandborn WJ, Vermeire S, Peyrin-Biroulet L, et al. Lancet 2023; 401: 1159-71.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jennifer Kolb, MD, MPH discuss “Magnitude and Time-Trends of Post-Endoscopy Esophageal Adenocarcinoma and Post-Endoscopy Esophageal Neoplasia in a Population-Based Cohort Study: The Nordic Barrett's Esophagus Study,” by Wani S, Holmberg D, Santonin G, et al. Gastroenterology 2023; 165:909-19.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Shria Kumar, MD, MSCE discuss “Surveillance for Presumed BD-IPMN of the Pancreas: Stability, Size, and Age Identify Targets for Discontinuation,” by Marchegiani G, Pollini T, Burelli A, et al. Gastroenterology 2023 Oct;165(4):1016-1024.e5

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Risk of Gastrointestinal Adverse Events Associated with Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss,” by Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. JAMA Medicine 2023; In Press.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Bharati Kochar, MD, MS discuss “Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial,” by Feagan BG, Sands BE, Sandborn WJ, et al. Lancet Gastroenterol Hepatol. 2023; 8: 307-20.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Rahul Dalal, MD, MPH discuss “Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial,” by Hanauer S, Liedert B, Balser S, et al. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):816-825. Epub 2021 Aug 11.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Sonali Paul, MD, MS discuss “Hepatitis C Treatment Initiation Among US Medicaid Enrollees,” by Kapadia SN, Zhang H, Gonzalez CJ, et al. JAMA Netw Open. 2023 Aug 1;6(8):e2327326.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jacqueline Gaulin discuss “Association of Proton Pump Inhibitor Use with Incident Dementia and Cognitive Decline in Older Adults: A Prospective Cohort Study,” by Mehta R, Kochra B, Zhou Z, et al. Gastroenterology 2023; 165: 564-72.

Philip Schoenfeld, MD, MSEd, MSc (Epi) and Jeffrey Lee, MD, MPH discuss “Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard?” by Corley DA, Jensen CD, Chubak J, Schottinger JE, Halm EA, Udaltsova N. Gastroenterology. [2023 Sep;165(3):784-787.e4].